ArticleIJU case reports2025
Adverse Outcome of a Solitary Fibrous Tumor Originating in the Bladder.
Article in IJU case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Solitary fibrous tumors originating in the bladder are extremely rare. While generally associated with favorable outcomes, some show invasive behavior. We report a case of a solitary fibrous tumor originating in the bladder that was treated with multimodal therapy. Case Presentation: A 68-year-old male presented with urinary retention. Imaging revealed a well-defined 6.0 cm mass compressing the prostate. A biopsy suggested stromal sarcoma. Robot-assisted cystoprostatectomy was performed. Pathological examination revealed a solitary fibrous tumor originating from the bladder invading the prostate. Despite negative margins, lung nodules and a pelvic mass appeared 43 months postoperatively. Initially, these were treated with pazopanib, followed by doxorubicin and eribulin due to disease progression. The patient eventually transitioned to palliative care and passed away 69 months after diagnosis. Conclusion: There are no effective systemic treatments for solitary fibrous tumors, which can lead to poor outcomes. Individualized treatment approaches are necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.